TDOCHealthcare · Health Information ServicesThe 24 Wall Street analysts covering Teladoc Health, Inc. hold a median 12-month price target of $7.5 — +19.4% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 66 of 100 as at 17 Sept 2026 — in the upper half.
Consensus tells you what everyone already believes. The model scores Teladoc Health, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Accruals (96): Reported profit is backed by cash, and the company is not expanding recklessly.
Volatility (22): The share price moves around a lot.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on TDOC, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +19.4% from it.
Of the 20 most recent actions, 2 moved their price target up and 3 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 3 Aug 2026 | Citigroup | Maintains | Neutral | $11 → $7.50 |
| 30 July 2026 | Canaccord Genuity | Maintains | Buy | $11 → $10 |
| 30 July 2026 | Evercore ISI Group | Maintains | In-Line | $10 → $7.50 |
| 21 July 2026 | Canaccord Genuity | Maintains | Buy | $10 → $11 |
| 21 July 2026 | Canaccord Genuity | Maintains | Buy | — |
| 7 July 2026 | B of A Securities | Maintains | Buy | $9.00 → $11 |
| 7 July 2026 | B of A Securities | Maintains | Buy | — |
| 5 May 2026 | Citigroup | Maintains | Neutral | — |
| 8 Apr 2026 | Evercore ISI Group | Maintains | In-Line | — |
| 26 Mar 2026 | Barclays | Maintains | Equal-Weight | — |
| 13 Mar 2026 | JP Morgan | Maintains | Neutral | — |
| 10 Mar 2026 | Deutsche Bank | Upgrade | Buy | — |
| 3 Mar 2026 | Citigroup | Maintains | Neutral | — |
| 3 Mar 2026 | Oppenheimer | Maintains | Outperform | — |
| 26 Feb 2026 | BMO Capital | Maintains | Market Perform | — |
| 26 Feb 2026 | Canaccord Genuity | Maintains | Buy | — |
| 26 Feb 2026 | Evercore ISI Group | Maintains | In-Line | — |
| 26 Feb 2026 | Leerink Partners | Maintains | Market Perform | — |
| 26 Feb 2026 | Piper Sandler | Reiterates | Overweight | — |
| 26 Feb 2026 | Stifel | Maintains | Hold | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. TDOC appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 17 Sept 2026, Teladoc Health, Inc. returned −20.5% against +17.0% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 90% of US stocks
Cheaper than 83% of US stocks
Cheaper than 75% of US stocks
Cheaper than 12% of US stocks
Higher than 21% of US stocks
Higher than 32% of US stocks
Higher than 82% of US stocks
Higher than 27% of US stocks
Higher than 22% of US stocks
Higher than 34% of US stocks
Higher than 34% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Teladoc Health, Inc. has a market value of $1.2B and an enterprise value of $1.5B.
Revenue in the twelve months to 30 June 2026: $2.5B. The latest quarter shrank 4.0% year on year.
Net income over the same four quarters: −$177.4M, a −7.1% net margin.
Diluted earnings per share, trailing twelve months: $−0.99.
Free cash flow in the twelve months to 30 June 2026: $118.1M, after $130.4M of capital spending.
Trailing P/E: −5.8×; forward P/E: −8.4× — the forward figure prices analyst consensus estimates, not reported earnings.
Teladoc Health, Inc. employs 4,648 people — $536K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Teladoc Health, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Teladoc (TDOC) shares closed the recent trading session at $6.28, falling 2.33% from their previous day's close even as the broader market rose. The stock declined in price during this trading period.
Why it matters — A TDOC watcher would note that the stock slid against a rising market, an underperformance worth tracking in its recent price action.
A Seeking Alpha analysis notes that Teladoc Health trades near multi-year lows despite meaningful free cash flow and manageable debt. It highlights that BetterHelp's decline is a drag, while Integrated Care's improving margins and rising revenue per member offer stabilization.
Why it matters — The article suggests Teladoc's valuation is extremely depressed, with Integrated Care potentially providing a stabilizing offset to the decline in BetterHelp's business.
Teladoc (TDOC) closed at $6.16 in the latest trading day, a +1.15% change from its previous close, outpacing the broader stock market on that day.
Why it matters — The stock's daily gain relative to the broader market may be of interest to TDOC watchers tracking short-term price movement.
The Motley Fool identifies Teladoc as one of two beaten-down stocks to avoid, noting that its business is making little progress despite expanding insurance coverage within one of its most important segments.
Why it matters — A TDOC watcher would care because a leading financial publication is advising investors to avoid the stock, citing a lack of meaningful business progress even as insurance coverage expands in a key segment.
Zacks Investment Research highlights Teladoc's Integrated Care segment, noting that it is driving profitability as chronic care offerings gain traction. The report suggests Integrated Care could become the company's key earnings driver and deserves more investor attention.
Why it matters — The Integrated Care business' growing profitability and role as a potential key earnings driver could be a significant factor in Teladoc's overall financial performance for investors to watch.
The 24 Wall Street analysts covering Teladoc Health, Inc. have a median 12-month price target of $7.5, with estimates ranging from $5.5 to $11. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 24 analysts covering Teladoc Health, Inc., 6 rate it a Buy, 18 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Teladoc Health, Inc. 66 out of 100 across roughly 4,600 US stocks as at 17 Sept 2026. None of this is personal advice — it does not consider your circumstances.
As at 17 Sept 2026, Teladoc Health, Inc. ranks 66 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Accruals (96 of 100).
No one can know that. What the data says: the median 12-month target from 24 analysts implies +19.4% from the last close, and Ticker Nerd's factor model ranks Teladoc Health, Inc. 66 out of 100 as at 17 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Teladoc Health, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for TDOC are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $5.5 to $11 over the next 12 months.
Teladoc Health, Inc. returned -20.5% over the 12 months to 17 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.
Teladoc Health Inc. is a virtual healthcare company that provides technology-enabled medical services for patients, employers, health plans, hospitals, and health systems.
The most recent item we track (Zacks Investment Research, 17 Sept 2026): "Teladoc (TDOC) Stock Slides as Market Rises: Facts to Know Before You Trade". Teladoc (TDOC) shares closed the recent trading session at $6.28, falling 2.33% from their previous day's close even as the broader market rose. The stock declined in price during this trading period.
Teladoc Health Inc. is a virtual healthcare company that provides technology-enabled medical services for patients, employers, health plans, hospitals, and health systems. Its platform supports remote access to general medical care, mental health services, chronic condition management, specialty consultations, and expert medical opinions through phone, video, mobile, and web-based channels. The company operates through two main business segments: Integrated Care, which delivers enterprise virtual care solutions, and BetterHelp, a direct-to-consumer online mental health platform. Teladoc Health Inc. plays a significant role in the digital health market by connecting clinicians and care seekers through scalable, on-demand care delivery across a broad range of healthcare needs.
CEO Mr. Charles Divita III, C.P.A. · 4,648 employees · United States · https://www.teladochealth.com
